{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+Chemistry", "query": { "intervention": "Blood Chemistry" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1177, "total_pages": 118, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+Chemistry&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T09:01:53.053Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03321643", "title": "Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Transformed Non-Hodgkin Lymphoma", "Richter Syndrome", "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-09-18", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-03T09:01:53.053Z", "location_count": 4, "location_summary": "Duarte, California • La Jolla, California • Sacramento, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03321643" }, { "nct_id": "NCT00919997", "title": "Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Nonneoplastic Condition", "Precancerous Condition" ], "interventions": [ { "name": "DNA analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "fluorescence activated cell sorting", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "study of socioeconomic and demographic variables", "type": "OTHER" }, { "name": "study of high risk factors", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 302, "start_date": "2009-07", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2015-10-05", "last_synced_at": "2026-09-03T09:01:53.053Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00919997" }, { "nct_id": "NCT05111574", "title": "Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Melanoma", "Bladder Melanoma", "Cervical Melanoma", "Esophageal Melanoma", "Gallbladder Melanoma", "Head and Neck Mucosal Melanoma", "Mucosal Melanoma", "Nasopharyngeal Mucosal Melanoma", "Oral Cavity Mucosal Melanoma", "Penile Mucosal Melanoma", "Rectal Melanoma", "Recurrent Mucosal Melanoma", "Sinonasal Mucosal Melanoma", "Urethral Melanoma", "Urinary System Mucosal Melanoma", "Vaginal Melanoma", "Vulvar Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2022-08-11", "completion_date": "2027-07-15", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-03T09:01:53.053Z", "location_count": 142, "location_summary": "Auburn, California • Berkeley, California • Fremont, California + 116 more", "locations": [ { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05111574" }, { "nct_id": "NCT04729959", "title": "Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Astrocytoma, IDH-Wildtype", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Fractionated Stereotactic Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2022-03-11", "completion_date": "2026-09-04", "has_results": true, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-03T09:01:53.053Z", "location_count": 110, "location_summary": "Anaheim, California • Bellflower, California • Los Angeles, California + 89 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729959" }, { "nct_id": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Histiocytic Sarcoma", "Juvenile Xanthogranuloma", "Langerhans Cell Histiocytosis", "Malignant Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Soft Tissue Sarcoma", "Refractory Ewing Sarcoma", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Rhabdoid Tumor", "Stage III Osteosarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Osteosarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Osteosarcoma AJCC v7", "Stage IVB Osteosarcoma AJCC v7", "Wilms Tumor" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Samotolisib", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Tipifarnib", "type": "DRUG" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1377, "start_date": "2017-07-31", "completion_date": "2027-01-06", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-03T09:01:53.053Z", "location_count": 168, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155620" }, { "nct_id": "NCT02958189", "title": "Tweet4Wellness: An Online Virtual Support Group for Promoting Increased Physical Activity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Physical Activity", "Social Media" ], "interventions": [ { "name": "Tweet4Wellness", "type": "BEHAVIORAL" }, { "name": "Self-monitoring", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2019-06-20", "completion_date": "2019-12-20", "has_results": false, "last_update_posted_date": "2020-04-10", "last_synced_at": "2026-09-03T09:01:53.053Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02958189" }, { "nct_id": "NCT06449287", "title": "Impact of Exogenous Ketones on Indices of Keto-Adaptation in Obese Subjects on Weight Reducing Diets.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ketogenic Diet", "Weight Loss" ], "interventions": [ { "name": "Diet", "type": "OTHER" }, { "name": "Blood Draw", "type": "BIOLOGICAL" }, { "name": "Ketone/Glucose Monitoring", "type": "BIOLOGICAL" }, { "name": "Body Composition", "type": "OTHER" }, { "name": "Urine Analysis", "type": "BIOLOGICAL" }, { "name": "Neuropsychological Measures - ANAM", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "BEHAVIORAL" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2018-07-05", "completion_date": "2019-08-21", "has_results": false, "last_update_posted_date": "2024-12-19", "last_synced_at": "2026-09-03T09:01:53.053Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06449287" }, { "nct_id": "NCT02953587", "title": "Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Oral Glucose Tolerance Test (OGTT)", "type": "PROCEDURE" }, { "name": "Human Ghrelin", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 70, "start_date": "2016-09", "completion_date": "2023-01-30", "has_results": false, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-09-03T09:01:53.053Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02953587" }, { "nct_id": "NCT05786040", "title": "Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder", "Polymorphic Post-Transplant Lymphoproliferative Disorder" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tafasitamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Timothy Voorhees", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2023-03-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-09-03T09:01:53.053Z", "location_count": 4, "location_summary": "New Brunswick, New Jersey • Hillsborough, North Carolina • Columbus, Ohio + 1 more", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Hillsborough", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05786040" }, { "nct_id": "NCT04684368", "title": "A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Nongerminomatous Germ Cell Tumor", "Choriocarcinoma", "Embryonal Carcinoma", "Immature Teratoma", "Malignant Teratoma", "Mixed Germ Cell Tumor", "Pineal Region Germ Cell Tumor", "Pineal Region Immature Teratoma", "Pineal Region Yolk Sac Tumor", "Suprasellar Germ Cell Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Second-Look Surgery", "type": "PROCEDURE" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "3 Years to 29 Years" }, "enrollment_count": 160, "start_date": "2021-07-13", "completion_date": "2029-12-21", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-03T09:01:53.053Z", "location_count": 152, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04684368" } ] }